Literature DB >> 2685006

Clinical review 3: The clinical use of thyrotropin receptor antibody measurements.

J M McKenzie1, M Zakarija.   

Abstract

There are relatively few circumstances wherein the assay of TRAb, as TSAb or TBIAb, is merited in the routine clinical management of patients with autoimmune thyroid disease. These include: 1. the prediction of neonatal hyperthyroidism; 2. the confirmation, by assay of maternal serum, and perhaps newborn blood, that neonatal hypothyroidism, identified on routine screening, may be transient and due to transplacental passage of TBIAb; 3. the prediction of relapse of hyperthyroidism at the end of a course of antithyroid drugs; this information should lead to more careful observation to identify relapse as early as possible; 4. the confirmation that adult agoitrous hypothyroidism reflects the effect of an antibody (TBIAb) blocking the action of TSH although, as discussed, there is little, if any, practical gain from this information. Additional applications of the routine use of TRAb assays will require the development of a procedure that combines the sensitivity, specificity, availability, and ease found variably in current TSAb and TBI procedures, and at much less cost than what is provided today.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685006     DOI: 10.1210/jcem-69-6-1093

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology.

Authors:  M P Vanderpump; J A Ahlquist; J A Franklyn; R N Clayton
Journal:  BMJ       Date:  1996-08-31

Review 2.  Immunity to the thyroid-stimulating hormone receptor.

Authors:  J Furmaniak; B R Smith
Journal:  Springer Semin Immunopathol       Date:  1993

3.  Unaltered thyroid function in mice responding to a highly immunogenic thyrotropin receptor: implications for the establishment of a mouse model for Graves' disease.

Authors:  G Carayanniotis; G C Huang; L B Nicholson; T Scott; P Allain; A M McGregor; J P Banga
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

4.  Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.

Authors:  R J Mullins; S B Cohen; L M Webb; Y Chernajovsky; C M Dayan; M Londei; M Feldmann
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism.

Authors:  C Ledent; J E Dumont; G Vassart; M Parmentier
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

Review 6.  Bioassays for TSH Receptor Autoantibodies, from FRTL-5 Cells to TSH Receptor-LH/CG Receptor Chimeras: The Contribution of Leonard D. Kohn.

Authors:  Cesidio Giuliani; Motoyasu Saji; Ines Bucci; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-25       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.